Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

December 30, 2026

Conditions

Esophageal Cancer

Interventions

DEVICE

Spectroscopy system

System that measures the fluorescence intensity in tissue in vivo.

DRUG

Nivolumab-800CW

Fluorescent tracer

DRUG

Durvalumab-680LT

Fluorescent tracer

All Listed Sponsors

collaborator

Martini Hospital Groningen

OTHER

lead

University Medical Center Groningen

OTHER